Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Kintara Therapeutics Inc (KTRA)

Kintara Therapeutics Inc (KTRA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 45,665
  • Shares Outstanding, K 32,618
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,130 K
  • 60-Month Beta 1.53
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
Trade KTRA with:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/21
See More
  • Average Estimate -0.12
  • Number of Estimates 2
  • High Estimate -0.08
  • Low Estimate -0.15
  • Prior Year -0.25
  • Growth Rate Est. (year over year) +52.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.2500 +12.00%
on 09/15/21
1.5900 -11.95%
on 09/01/21
-0.0900 (-6.04%)
since 08/17/21
3-Month
1.2500 +12.00%
on 09/15/21
2.8500 -50.88%
on 07/01/21
-0.5000 (-26.32%)
since 06/17/21
52-Week
1.1800 +18.64%
on 11/10/20
3.3500 -58.21%
on 02/10/21
-0.0700 (-4.76%)
since 09/17/20

Most Recent Stories

More News
Housing Data at Centre Stage Next Week

Monday U.S. Economic Lookahead NAHB Housing Market Index (Sept.) Featured Earnings Kintara Therapeutics ...

AZO : 1,592.88 (-0.90%)
DAVA : 133.64 (-2.30%)
GIS : 58.92 (+0.34%)
JEF : 36.54 (+0.25%)
FUL : 60.72 (-2.58%)
NKE : 156.42 (-0.75%)
ACN : 335.40 (-2.00%)
DRI : 149.43 (-0.58%)
TCOM : 28.82 (+0.73%)
PZG : 0.8502 (+2.43%)
KTRA : 1.4000 (+6.06%)
ADBE : 654.48 (-1.60%)
CTAS : 392.86 (-1.67%)
COST : 459.51 (-0.82%)
Kintara Therapeutics Provides Positive Site Activation Update on GCAR Phase 2/3 Clinical Trial for Glioblastoma

/PRNewswire/ -- (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced that the VAL-083 treatment arm...

KTRA : 1.4000 (+6.06%)
Kintara Therapeutics to Present at the Investor Summit Virtual Conference on August 17, 2021

/PRNewswire/ -- . (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that its Chief...

KTRA : 1.4000 (+6.06%)
Kintara Therapeutics to Present at the BTIG Virtual Biotechnology Conference on August 9, 2021

/PRNewswire/ -- . (Nasdaq: KTRA), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens, announced today that , Chief...

KTRA : 1.4000 (+6.06%)
Biotech Stock Roundup: ALEC Surges on Deal With GSK, CVAC Down on Study Results & More

The biotech sector was in focus last week on the collaboration news from Alector (ALEC) and pipeline updates from CureVac (CVAC).

GSK : 38.93 (-0.46%)
PFE : 43.89 (-1.30%)
SPRO : 19.15 (+0.52%)
ALEC : 26.81 (+5.30%)
CVAC : 55.11 (unch)
KTRA : 1.4000 (+6.06%)
Thinking about buying stock in Kintara Therapeutics, US Well Services, Transocean, Marathon Oil, or Cerevel Therapeutics?

/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KTRA, USWS, RIG, MRO, and CERE.

CERE : 37.57 (+2.99%)
KTRA : 1.4000 (+6.06%)
USWS : 0.6865 (-2.03%)
MRO : 12.00 (-2.60%)
RIG : 3.35 (-3.46%)
Kintara Reports Topline Results From Phase 2 Clinical Trial of VAL-083 for Recurrent GBM

/PRNewswire/ --  (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company developing novel cancer therapies for patients who are failing or are resistant to current treatment regimens,...

KTRA : 1.4000 (+6.06%)
Kintara Therapeutics Set to Join Russell Microcap® Index

  , /PRNewswire/ --  (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced Kintara's addition to...

KTRA : 1.4000 (+6.06%)
Kintara Therapeutics Enrolls Final Patient in Phase 2 Clinical Trial of VAL-083 for Adjuvant Treatment of Brain Tumors

, /PRNewswire/ --  (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced it has enrolled the final patient...

KTRA : 1.4000 (+6.06%)
Kintara Therapeutics to Present at the LD Micro Virtual Invitational Conference on June 9, 2021

, /PRNewswire/ -- . (Nasdaq: KTRA), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, announced today that Chief Executive Officer will present a corporate...

KTRA : 1.4000 (+6.06%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Kintara Therapeutics Inc. is a biopharmaceutical company. It is focused on the development of new solid tumor cancer therapies. The company's program includes VAL-083 for GBM and REM-001 for cutaneous metastatic breast cancer, which are in clinical stage. Kintara Therapeutics Inc. is based in San Diego,...

See More

Key Turning Points

3rd Resistance Point 1.5333
2nd Resistance Point 1.4667
1st Resistance Point 1.4333
Last Price 1.4000
1st Support Level 1.3333
2nd Support Level 1.2667
3rd Support Level 1.2333

See More

52-Week High 3.3500
Fibonacci 61.8% 2.5211
Fibonacci 50% 2.2650
Fibonacci 38.2% 2.0089
Last Price 1.4000
52-Week Low 1.1800

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar